94 results
CORRESP
FGEN
FibroGen Inc
21 Feb 20
Correspondence with SEC
12:00am
by the principal investigator to be related to, or possibly related to Pamrevlumab. Alternatively, please disclose clearly that upon investigation … designated as “possibly related to study treatment” by the principal investigator) to clearly state that upon our investigation, it is our belief
8-K
EX-99.1
qbazqt
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
735 tp0x2dgcucfm
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
g8j77xa2
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
yayhlpkemmj2nc
26 Sep 19
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment
9:01am
CORRESP
y6oo5a2zea4n jd3yelz
31 Jan 20
Correspondence with SEC
12:00am
8-K
EX-99.1
2ndjghv
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
lg7 hu3vs
8 Aug 22
FibroGen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
EX-99.1
8fs61340
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
k3e8k69bt0crik vv5t
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
co8wqq5a
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
6lrx 1p9nih
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
j3f0vp6i
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
S-1
EX-4.3
2l5ek0 nmqnaby2xyai
1 Oct 14
IPO registration
12:00am
S-1
EX-4.6
grq9y1lcc fe
1 Oct 14
IPO registration
12:00am